Overview

Scientific Rationale: High risk localized prostate cancer (PCa) is associated with higher rates of biochemical recurrence, clinical recurrence, metastasis and PCa-specific death. Novel hormone therapies(NHT) have shown a significant survival advantage with respect to classical ADT in later stages of PCa and have already been investigated in neoadjuvant setting.

PURPOSE: To assess antitumor effect by measuring pathological tumor volume with pathological downstaging following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for high-risk localized prostate cancer patients.

Eligibility

Inclusion Criteria:

1. Male ≥18 years of age.
2. Able to Sign informed consent form independently.
3. Non-metastatic adenocarcinoma of the prostate.
4. Subjects must have as least one of the following features according to NCCN definition of high-risk: Gleason score ≥8, or PSA >20ng/ml,or≥clinical T3a.
5. Subjects with pelvic lymph node involvement(N1) can be included.
6. Candidate for radical prostatectomy with or without pelvic lymph node dissection as per the investigator.
7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
8. Subjects must have normal organ and marrow function as defined below:

        Hemoglobin ≥ 9.0 g/dL;Absolute neutrophil count (ANC) ≥ 1,500/mcL; Platelets ≥ 100,000/mcL,
        independent of transfusions/growth factors within 3 months of treatment start; Serum
        potassium ≥ 3.5 mmol/L; Serum total bilirubin ≤ 2.0 x upper limit of normal (ULN) (except
        in subjects with Gilbert's syndrome who have a total bilirubin > 1.5 x ULN, measure direct
        and indirect bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject may be
        eligible);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x
        ULN;Serum albumin ≥ 3.0 g/dL;Serum creatinine < 2.0 x ULN.
        Exclusion Criteria:
          1. Prostate cancer with neuroendocrine differentiation or small cell features
          2. Distant metastasis based on conventional imaging (clinical stage M1). Nodal disease
             below the iliac bifurcation (clinical stage N1) is not an exclusion.
          3. History of prior systemic or local therapy for prostate cancer, including pelvic
             radiation for prostate cancer.
          4. Subjects who are planning bilateral orchidectomy during the treatment period of the
             study.
          5. Intolerable with darolutamide or ADT treatment.
          6. Candidates of other clinical trials.
          7. Any prior malignancy within 5 years.
          8. Complications include significant cardiovascular disease, active infection,
             astrointestinal disorders, or any other complications that in the opinion of the
             investigator.
          9. Any condition that in the opinion of the investigator would preclude participation in
             this study.